

Representative Ann W. Hardy proposes the following substitute bill:

CONTROLLED SUBSTANCE AMENDMENT

2006 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Ann W. Hardy

Senate Sponsor: _____

LONG TITLE

General Description:

This bill modifies the Utah Controlled Substances Act by moving buprenorphine from Schedule III to Schedule II in the controlled substance schedules.

Highlighted Provisions:

This bill:

► changes buprenorphine, which has the brand name of Suboxone, from a Schedule III controlled substance to a Schedule II controlled substance.

Monies Appropriated in this Bill:

None

Other Special Clauses:

None

Utah Code Sections Affected:

AMENDS:

58-37-4, as last amended by Chapter 33, Laws of Utah 2003

Be it enacted by the Legislature of the state of Utah:

Section 1. Section **58-37-4** is amended to read:

58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings



required -- Specific substances included in schedules.

(1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V which shall consist of substances listed in this section.

(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official name, common or usual name, chemical name, or brand name designated:

(a) Schedule I:

(i) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation:

(A) Acetyl-alpha-methylfentanyl

(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

(B) Acetylmethadol;

(C) Allylprodine;

(D) Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;

(E) Alphameprodine;

(F) Alphamethadol;

(G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N- propanilido) piperidine);

(H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

(I) Benzethidine;

(J) Betacetylmethadol;

(K) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);

(L) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;

(M) Betameprodine;

(N) Betamethadol;

(O) Betaprodine;

- 57 (P) Clonitazene;
58 (Q) Dextromoramide;
59 (R) Diampromide;
60 (S) Diethylthiambutene;
61 (T) Difenoxin;
62 (U) Dimenoxadol;
63 (V) Dimepheptanol;
64 (W) Dimethylthiambutene;
65 (X) Dioxaphetyl butyrate;
66 (Y) Dipipanone;
67 (Z) Ethylmethylthiambutene;
68 (AA) Etonitazene;
69 (BB) Etoxeridine;
70 (CC) Furethidine;
71 (DD) Hydroxypethidine;
72 (EE) Ketobemidone;
73 (FF) Levomoramide;
74 (GG) Levophenacymorphan;
75 (HH) Morpheridine;
76 (II) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
77 (JJ) Noracymethadol;
78 (KK) Norlevorphanol;
79 (LL) Normethadone;
80 (MM) Norpipanone;
81 (NN) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidiny] propanamide;
82
83 (OO) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
84 (PP) Phenadoxone;
85 (QQ) Phenampromide;
86 (RR) Phenomorphan;
87 (SS) Phenoperidine;

- 88 (TT) Piritramide;
89 (UU) Proheptazine;
90 (VV) Properidine;
91 (WW) Propiram;
92 (XX) Racemoramide;
93 (YY) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
94 (ZZ) Tilidine;
95 (AAA) Trimeperidine;
96 (BBB) 3-methylfentanyl, including the optical and geometric isomers
97 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
98 (CCC) 3-methylthiofentanyl
99 (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
- 100 (ii) Unless specifically excepted or unless listed in another schedule, any of the
101 following opium derivatives, their salts, isomers, and salts of isomers when the existence of the
102 salts, isomers, and salts of isomers is possible within the specific chemical designation:
- 103 (A) Acetorphine;
104 (B) Acetyldihydrocodeine;
105 (C) Benzylmorphine;
106 (D) Codeine methylbromide;
107 (E) Codeine-N-Oxide;
108 (F) Cyprenorphine;
109 (G) Desomorphine;
110 (H) Dihydromorphine;
111 (I) Drotebanol;
112 (J) Etorphine (except hydrochloride salt);
113 (K) Heroin;
114 (L) Hydromorphenol;
115 (M) Methyldesorphine;
116 (N) Methylhydromorphine;
117 (O) Morphine methylbromide;
118 (P) Morphine methylsulfonate;

119 (Q) Morphine-N-Oxide;

120 (R) Myrophine;

121 (S) Nicocodeine;

122 (T) Nicomorphine;

123 (U) Normorphine;

124 (V) Pholcodine; and

125 (W) Thebacon.

126 (iii) Unless specifically excepted or unless listed in another schedule, any material,
127 compound, mixture, or preparation which contains any quantity of the following hallucinogenic
128 substances, or which contains any of their salts, isomers, and salts of isomers when the
129 existence of the salts, isomers, and salts of isomers is possible within the specific chemical
130 designation; as used in this Subsection (2)(iii) only, "isomer" includes the optical, position, and
131 geometric isomers:

132 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
133 α -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;

134 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
135 4-bromo-2,5-dimethoxy- α -methylphenethylamine; 4-bromo-2,5-DMA;

136 (C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:
137 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;

138 (D) 2,5-dimethoxyamphetamine, some trade or other names:
139 2,5-dimethoxy- α -methylphenethylamine; 2,5-DMA;

140 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;

141 (F) 4-methoxyamphetamine, some trade or other names:
142 4-methoxy- α -methylphenethylamine; paramethoxyamphetamine, PMA;

143 (G) 5-methoxy-3,4-methylenedioxyamphetamine;

144 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
145 4-methyl-2,5-dimethoxy- α -methylphenethylamine; "DOM"; and "STP";

146 (I) 3,4-methylenedioxy amphetamine;

147 (J) 3,4-methylenedioxymethamphetamine (MDMA);

148 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
149 alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;

150 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
151 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
152 (M) 3,4,5-trimethoxy amphetamine;
153 (N) Bufotenine, some trade and other names:
154 3-(β -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,
155 N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
156 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
157 (P) Dimethyltryptamine, some trade or other names: DMT;
158 (Q) Ibogaine, some trade and other names:
159 7-Ethyl-6,6 β ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
160 [5,4-b] indole; Tabernanthe iboga;
161 (R) Lysergic acid diethylamide;
162 (S) Marijuana;
163 (T) Mescaline;
164 (U) Parahexyl, some trade or other names:
165 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
166 (V) Peyote, meaning all parts of the plant presently classified botanically as
167 *Lophophora williamsii* Lemaire, whether growing or not, the seeds thereof, any extract from
168 any part of such plant, and every compound, manufacture, salts, derivative, mixture, or
169 preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
170 (W) N-ethyl-3-piperidyl benzilate;
171 (X) N-methyl-3-piperidyl benzilate;
172 (Y) Psilocybin;
173 (Z) Psilocyn;
174 (AA) Tetrahydrocannabinols, synthetic equivalents of the substances contained in the
175 plant, or in the resinous extractives of *Cannabis*, sp. and/or synthetic substances, derivatives,
176 and their isomers with similar chemical structure and pharmacological activity such as the
177 following: Δ 1 cis or trans tetrahydrocannabinol, and their optical isomers Δ 6 cis or trans
178 tetrahydrocannabinol, and their optical isomers Δ 3,4 cis or trans tetrahydrocannabinol, and its
179 optical isomers, and since nomenclature of these substances is not internationally standardized,
180 compounds of these structures, regardless of numerical designation of atomic positions

181 covered;

182 (BB) Ethylamine analog of phencyclidine, some trade or other names:

183 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,

184 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;

185 (CC) Pyrrolidine analog of phencyclidine, some trade or other names:

186 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;

187 (DD) Thiophene analog of phencyclidine, some trade or other names:

188 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and

189 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.

190 (iv) Unless specifically excepted or unless listed in another schedule, any material

191 compound, mixture, or preparation which contains any quantity of the following substances

192 having a depressant effect on the central nervous system, including its salts, isomers, and salts

193 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the

194 specific chemical designation:

195 (A) Mecloqualone; and

196 (B) Methaqualone.

197 (v) Any material, compound, mixture, or preparation containing any quantity of the

198 following substances having a stimulant effect on the central nervous system, including their

199 salts, isomers, and salts of isomers:

200 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or

201 4,5-dihydro-5-phenyl-2-oxazolamine;

202 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,

203 alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;

204 (C) Fenethylamine;

205 (D) Methcathinone, some other names: 2-(methylamino)-propionophenone;

206 alpha-(methylamino)propionophenone; 2-(methylamino)-1-phenylpropan-1-one;

207 alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;

208 methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of

209 optical isomers;

210 (E) (\pm)cis-4-methylaminorex ((\pm)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);

211 (F) N-ethylamphetamine; and

- 212 (G) N,N-dimethylamphetamine, also known as
213 N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
- 214 (vi) Any material, compound, mixture, or preparation which contains any quantity of
215 the following substances, including their optical isomers, salts, and salts of isomers, subject to
216 temporary emergency scheduling:
- 217 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
218 (B) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
- 219 (vii) Unless specifically excepted or unless listed in another schedule, any material,
220 compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
221 (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
- 222 (b) Schedule II:
- 223 (i) Unless specifically excepted or unless listed in another schedule, any of the
224 following substances whether produced directly or indirectly by extraction from substances of
225 vegetable origin, or independently by means of chemical synthesis, or by a combination of
226 extraction and chemical synthesis:
- 227 (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
228 opiate, excluding apomorphine, dextrophan, nalbuphine, nalmeferine, naloxone, and naltrexone,
229 and their respective salts, but including:
- 230 (I) Raw opium;
231 (II) Opium extracts;
232 (III) Opium fluid;
233 (IV) Powdered opium;
234 (V) Granulated opium;
235 (VI) Tincture of opium;
236 (VII) Codeine;
237 (VIII) Ethylmorphine;
238 (IX) Etorphine hydrochloride;
239 (X) Hydrocodone;
240 (XI) Hydromorphone;
241 (XII) Metopon;
242 (XIII) Morphine;

243 (XIV) Oxycodone;
244 (XV) Oxymorphone; and
245 (XVI) Thebaine;
246 (B) Any salt, compound, derivative, or preparation which is chemically equivalent or
247 identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
248 substances may not include the isoquinoline alkaloids of opium;
249 (C) Opium poppy and poppy straw;
250 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
251 any salt, compound, derivative, or preparation which is chemically equivalent or identical with
252 any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,
253 and salts of isomers and derivatives, whether derived from the coca plant or synthetically
254 produced, except the substances may not include decocainized coca leaves or extraction of coca
255 leaves, which extractions do not contain cocaine or ecgonine; and
256 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either
257 liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
258 (ii) Unless specifically excepted or unless listed in another schedule, any of the
259 following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
260 ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
261 chemical designation, except dextrorphan and levopropoxyphene:
262 (A) Alfentanil;
263 (B) Alphaprodine;
264 (C) Anileridine;
265 (D) Bezitramide;
266 (E) Bulk dextropropoxyphene (nondosage forms);
267 (F) Buprenorphine;
268 [~~F~~] (G) Carfentanil;
269 [~~G~~] (H) Dihydrocodeine;
270 [~~H~~] (I) Diphenoxylate;
271 [~~I~~] (J) Fentanyl;
272 [~~J~~] (K) Isomethadone;
273 [~~K~~] (L) Levo-alpha-acetylmethadol, some other names: levo-alpha-acetylmethadol,

- 274 levomethadyl acetate, or LAAM;
275 [~~(H)~~] (M) Levomethorphan;
276 [~~(M)~~] (N) Levorphanol;
277 [~~(N)~~] (O) Metazocine;
278 [~~(O)~~] (P) Methadone;
279 [~~(P)~~] (Q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
280 [~~(Q)~~] (R) Moramide-Intermediate, 2-methyl-3-morpholino-1,
281 1-diphenylpropane-carboxylic acid;
282 [~~(R)~~] (S) Pethidine (meperidine);
283 [~~(S)~~] (T) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
284 [~~(T)~~] (U) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
285 [~~(U)~~] (V) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
286 [~~(V)~~] (W) Phenazocine;
287 [~~(W)~~] (X) Piminodine;
288 [~~(X)~~] (Y) Racemethorphan;
289 [~~(Y)~~] (Z) Racemorphan;
290 [~~(Z)~~] (AA) Remifentanyl; and
291 [~~(AA)~~] (BB) Sufentanyl.
292 (iii) Unless specifically excepted or unless listed in another schedule, any material,
293 compound, mixture, or preparation which contains any quantity of the following substances
294 having a stimulant effect on the central nervous system:
295 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
296 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
297 (C) Phenmetrazine and its salts; and
298 (D) Methylphenidate.
299 (iv) Unless specifically excepted or unless listed in another schedule, any material,
300 compound, mixture, or preparation which contains any quantity of the following substances
301 having a depressant effect on the central nervous system, including its salts, isomers, and salts
302 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
303 specific chemical designation:
304 (A) Amobarbital;

- 305 (B) Glutethimide;
306 (C) Pentobarbital;
307 (D) Phencyclidine;
308 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
309 1-piperidinocyclohexanecarbonitrile (PCC); and
310 (F) Secobarbital.
- 311 (v) Unless specifically excepted or unless listed in another schedule, any material,
312 compound, mixture, or preparation which contains any quantity of Phenylacetone.
- 313 Some of these substances may be known by trade or other names: phenyl-2-propanone,
314 P2P; benzyl methyl ketone, methyl benzyl ketone.
- 315 (vi) Nabilone, another name for nabilone:
316 (±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
317 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
- 318 (c) Schedule III:
- 319 (i) Unless specifically excepted or unless listed in another schedule, any material,
320 compound, mixture, or preparation which contains any quantity of the following substances
321 having a stimulant effect on the central nervous system, including its salts, isomers whether
322 optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers,
323 and salts of isomers is possible within the specific chemical designation:
- 324 (A) Those compounds, mixtures, or preparations in dosage unit form containing any
325 stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were
326 listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the
327 Code of Federal Regulations, and any other drug of the quantitative composition shown in that
328 list for those drugs or which is the same except that it contains a lesser quantity of controlled
329 substances;
- 330 (B) Benzphetamine;
331 (C) Chlorphentermine;
332 (D) Clortermine; and
333 (E) Phendimetrazine.
- 334 (ii) Unless specifically excepted or unless listed in another schedule, any material,
335 compound, mixture, or preparation which contains any quantity of the following substances

336 having a depressant effect on the central nervous system:

337 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
338 pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients
339 which are not listed in any schedule;

340 (B) Any suppository dosage form containing amobarbital, secobarbital, or
341 pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug
342 Administration for marketing only as a suppository;

343 (C) Any substance which contains any quantity of a derivative of barbituric acid or any
344 salt of any of them;

345 (D) Chlorhexadol;

346 [~~(E)~~] ~~Buprenorphine~~;

347 [~~(F)~~] (E) Any drug product containing gamma hydroxybutyric acid, including its salts,
348 isomers, and salts of isomers, for which an application is approved under the federal Food,
349 Drug, and Cosmetic Act, Section 505;

350 [~~(G)~~] (F) Ketamine, its salts, isomers, and salts of isomers, some other names for
351 ketamine: \pm -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone.

352 [~~(H)~~] (G) Lysergic acid;

353 [~~(I)~~] (H) Lysergic acid amide;

354 [~~(J)~~] (I) Methypylon;

355 [~~(K)~~] (J) Sulfondiethylmethane;

356 [~~(L)~~] (K) Sulfonethylmethane;

357 [~~(M)~~] (L) Sulfonmethane; and

358 [~~(N)~~] (M) Tiletamine and zolazepam or any of their salts, some trade or other names
359 for a tiletamine-zolazepam combination product: Telazol, some trade or other names for
360 tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for
361 zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]
362 [1,4]-diazepin-7(1H)-one, flupyrzapon.

363 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
364 U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
365 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or
366 (-)-delta-9-(trans)-tetrahydrocannabinol.

(iv) Nalorphine.

(v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:

(A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;

(C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;

(D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

(E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;

(F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;

(G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; and

(H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts.

(vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids including any of the following or any isomer, ester, salt, or derivative of the following that promotes muscle growth:

(A) Boldenone;

- 398 (B) Chlorotestosterone (4-chlortestosterone);
- 399 (C) Clostebol;
- 400 (D) Dehydrochlormethyltestosterone;
- 401 (E) Dihydrotestosterone (4-dihydrotestosterone);
- 402 (F) Drostanolone;
- 403 (G) Ethylestrenol;
- 404 (H) Fluoxymesterone;
- 405 (I) Formebolone (formebolone);
- 406 (J) Mesterolone;
- 407 (K) Methandienone;
- 408 (L) Methandranone;
- 409 (M) Methandriol;
- 410 (N) Methandrostenolone;
- 411 (O) Methenolone;
- 412 (P) Methyltestosterone;
- 413 (Q) Mibolerone;
- 414 (R) Nandrolone;
- 415 (S) Norethandrolone;
- 416 (T) Oxandrolone;
- 417 (U) Oxymesterone;
- 418 (V) Oxymetholone;
- 419 (W) Stanolone;
- 420 (X) Stanozolol;
- 421 (Y) Testolactone;
- 422 (Z) Testosterone; and
- 423 (AA) Trenbolone.

424 Anabolic steroids expressly intended for administration through implants to cattle or
425 other nonhuman species, and approved by the Secretary of Health and Human Services for use,
426 may not be classified as a controlled substance.

427 (d) Schedule IV:

428 (i) Unless specifically excepted or unless listed in another schedule, any material,

429 compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not
430 less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.

431 (ii) Unless specifically excepted or unless listed in another schedule, any material,
432 compound, mixture, or preparation which contains any quantity of the following substances,
433 including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and
434 salts of isomers is possible within the specific chemical designation:

- 435 (A) Alprazolam;
- 436 (B) Barbitol;
- 437 (C) Bromazepam;
- 438 (D) Butorphanol;
- 439 (E) Camazepam;
- 440 (F) Chloral betaine;
- 441 (G) Chloral hydrate;
- 442 (H) Chlordiazepoxide;
- 443 (I) Clobazam;
- 444 (J) Clonazepam;
- 445 (K) Clorazepate;
- 446 (L) Clotiazepam;
- 447 (M) Cloxazolam;
- 448 (N) Delorazepam;
- 449 (O) Diazepam;
- 450 (P) Dichloralphenazone;
- 451 (Q) Estazolam;
- 452 (R) Ethchlorvynol;
- 453 (S) Ethinamate;
- 454 (T) Ethyl loflazepate;
- 455 (U) Fludiazepam;
- 456 (V) Flunitrazepam;
- 457 (W) Flurazepam;
- 458 (X) Halazepam;
- 459 (Y) Haloxazolam;

460 (Z) Ketazolam;
461 (AA) Loprazolam;
462 (BB) Lorazepam;
463 (CC) Lormetazepam;
464 (DD) Mebutamate;
465 (EE) Medazepam;
466 (FF) Meprobamate;
467 (GG) Methohexital;
468 (HH) Methylphenobarbital (mephobarbital);
469 (II) Midazolam;
470 (JJ) Nimetazepam;
471 (KK) Nitrazepam;
472 (LL) Nordiazepam;
473 (MM) Oxazepam;
474 (NN) Oxazolam;
475 (OO) Paraldehyde;
476 (PP) Pentazocine;
477 (QQ) Petrichloral;
478 (RR) Phenobarbital;
479 (SS) Pinazepam;
480 (TT) Prazepam;
481 (UU) Quazepam;
482 (VV) Temazepam;
483 (WW) Tetrazepam;
484 (XX) Triazolam;
485 (YY) Zaleplon; and
486 (ZZ) Zolpidem.
487 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
488 any quantity of the following substances, including its salts, isomers whether optical, position,
489 or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of
490 isomers is possible.

(iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric isomers, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

(A) Cathine ((+)-norpseudoephedrine);

(B) Diethylpropion;

(C) Fencamfamine;

(D) Fenproporex;

(E) Mazindol;

(F) Mefenorex;

(G) Modafinil;

(H) Pemoline, including organometallic complexes and chelates thereof;

(I) Phentermine;

(J) Pipradrol;

(K) Sibutramine; and

(L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

(v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.

(e) Schedule V: Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

(i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;

(ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;

(iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;

(iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of

522 atropine sulfate per dosage unit;
523 (v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
524 (vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
525 atropine sulfate per dosage unit; and
526 (vii) unless specifically exempted or excluded or unless listed in another schedule, any
527 material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant
528 effect on the central nervous system, including its salts, isomers, and salts of isomers.